Clinical trials: BIS
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Fluid and Electrolyte Imbalance, Overhydration
Contributing Factors to Local Bioimpedance Spectroscopy
This is an exploratory interventional study. The aim of the investigation is to identify and quantify contributing factors to local bioimpedance spectroscopy (BIS) measured by a wearable sensor patch, particularly the effect of…
- Conditions
- Fluid and Electrolyte Imbalance, Overhydration, Edema
- Trial name
- COBI (NCT06003205)
- Testing
- Wearable bioimpedance sensor
- Where
- Norway
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Mode Sensors AS
Anesthesia
Evaluation of Bispectral Index (BIS™) and Levels of Sedation With Common Inhalational Anesthetics in Healthy Volunteers (OLIVER)
To investigate the relationship between BIS™ and inhaled anesthetics across a wide range of anesthetic concentration and hypnotic states, and to provide evidence to support BIS™ performance in use with Isoflurane, Sevoflurane and…
- Trial name
- OLIVER (NCT04602546)
- Testing
- BIS Complete Monitoring System
- Where
- 3 sites in United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Healthy
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 13.3 mg/24 h (Luye Pharma AG, Germany) and the marketed…
- Trial name
- NCT05853341
- Testing
- RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.